🇺🇸 FDA
Pipeline program

Onapristone ER

19-061

Phase 2 small_molecule completed

Quick answer

Onapristone ER for Granulosa Cell Ovarian Cancer is a Phase 2 program (small_molecule) at Context Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Context Therapeutics
Indication
Granulosa Cell Ovarian Cancer
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials